docetaxel oral/ritonavir (ModraDoc006/r) / Modra Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
docetaxel oral/ritonavir (ModraDoc006/r) / Modra Pharma
NCT03890744 / 2018-003249-41: ModraDoc006/r in Patients With Breast Cancer

Completed
2a
12
Europe
ModraDoc006/r, oral docetaxel formulation
Modra Pharmaceuticals
Metastatic Breast Cancer, Recurrent Breast Cancer
02/20
11/20
NCT04028388 / 2019-000582-21: ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Completed
2
135
Europe, US, RoW
Docetaxel in Parenteral Dosage Form, Taxotere, ModraDoc006/r, oral docetaxel formulation
Modra Pharmaceuticals
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
11/21
11/21

Download Options